cetuximab
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
July, 2024
July 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Jun
cetuximab
Jul 14, 2024, 07:59 |
Blog
New drug from Erasca in combination with cetuximab - Chordoma Foundation
Chordoma Foundation shared a post on X: “Promising results have emerged from a Phase 1…
Jul 11, 2024, 06:37 |
Insight
Results of the Complete Review on Targeted Therapies for Advanced Urothelial Carcinoma
María Natalia Gandur Quiroga shared on X: " Results and Main Messages of the Complete…
Jun 27, 2024, 18:05 |
Drugs
Adagrasib plus Cetuximab shows efficacy and safety in metastatic colorectal cancer
Iván R. González, Medical Oncologist at Centro Oncológico Integral, shared on X: "In the KRYSTAL-1…
Jun 25, 2024, 07:47 |
Blog
Mark Lewis: It is UNACCEPTABLE to treat mCRC without knowing these biomarker
Mark Lewis shared a post by FDA Oncology on X, adding the following: . “We…
Jun 22, 2024, 15:13 |
Drugs
Vivek Subbiah: Another FDA approval to adagrasib plus cetuximab for KRAS G12C-mutated colorectal cancer
Vivek Subbiah shared on LinkedIn: "It's Friday and time for another FDA approval! FDA grants…
Jun 22, 2024, 14:35 |
Drugs
FDA grants accelerated approval to adagrasib with cetuximab for KRAS G12C-mutated colorectal cancer
FDA Oncology shared on X: "FDA grants accelerated approval to adagrasib with cetuximab for KRAS…
Jun 21, 2024, 04:41 |
Insight
Davide Ciardiello: Cetuximab and Avelumab in patients with colorectal cancer liver metastasis
Davide Ciardiello, Oncologist at the Medical Oncology Division of Gastrointestinal and Neuroendocrine Tumors at European…
Apr 17, 2024, 13:11 |
Insight
New Paper Alert! Exploring Treatment Strategies After Progression to BRAF V600E-Targeted Therapy in Metastatic Colorectal Cancer: A Real-World Analysis
New Paper Alert: Exploring Treatment Strategies After Progression to BRAF V600E-Targeted Therapy in Metastatic Colorectal…
Apr 16, 2024, 11:36 |
Insight
Piotr Wysocki: Rechallenge with anti-EGFR antibodies is a feasible and safe strategy in refractory metastatic colorectal cancer patients with RAS/BRAFwt ctDNA
Piotr Wysocki, Professor of Medicine and Head of the Department of Oncology at Jagiellonian University…
Apr 12, 2024, 12:10 |
Insight
Piotr Wysocki: Cetuximab monotherapy maintenance after FOLFIRI may not be the optimal choice but can be considered in selected mCRC patients
Piotr Wysocki, Professor of Medicine and Head of the Department of Oncology at Jagiellonian University…
Apr 11, 2024, 15:23 |
Drugs
Piotr Wysocki: Adagrasib and cetuximab in KRAS G12C-mutated colorectal cancer is a safe and active
Piotr Wysocki, Professor of Medicine and Head of the Department of Oncology at Jagiellonian University…
Mar 16, 2024, 20:07 |
Insight
Erman Akkus: HER2 and mCRC on Journal of Clinical Oncology
Erman Akkus, Medical Oncology Fellow at Ankara University, shared on X/Twitter: "HER2 and mCRC on…
Jan 30, 2024, 19:29 |
Blog
Vrouyr Bilemjian: We have developed a tumor targeting drug delivery systems
Vrouyr Bilemjian, Solutions and Strategy Consultant at Innoplexus, made the following post on LinkedIn: "Excited…
Jan 10, 2024, 18:21 |
Blog
Top Precision Oncology articles of 2023 by Vivek Subbiah
Vivek Subbiah shared on X/Twitter: "By popular demand delighted to share the 'Top Precision Oncology…
All:
14
Posts:
1 - 100
The largest philanthropic partnership in The V Foundation’s history - Dolphins Cancer Challenge
Glecirasib: A Promising Novel KRAS G12C Inhibitor in Clinical Development
How the Médecins Sans Frontières Journal Inspired a Lifetime of Humanitarian Service: Paul Spiegel
OncoDaily Party and Yvonne Award Photos - Part 1
Michael Douglas: The Untold Story of His Battle Against Cancer
Facebook
RSS Feed
Twitter
Linkedin
Youtube